Press releaseBusiness Wire
Fulgent Genetics
FLGT · NASDAQ
$20.33+$0.23 (+1.14%)TodayMarket closed ·
Prev close $20.10
Latest news
- NewsAvi Kapoor
Apple, Stryker, Coinbase And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
Fulgent Genetics Q2 Adj. EPS $(0.58) Misses $(0.46) Estimate, Sales $85.389M Miss $94.000M Estimate
- Press releaseBusiness Wire
Fulgent Reports Second Quarter 2026 Financial Results
- Press releaseBusiness Wire
Fulgent to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
- Press releaseBusiness Wire
Fulgent Presents Updated FID-007 Data at ASCO 2026
- Press releaseBusiness Wire
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
- Press releaseGlobe Newswire
Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
- Press releaseBusiness Wire
Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics
- News
Full Transcript: Fulgent Genetics Q1 2026 Earnings Call
- News
Earnings Scheduled For May 1, 2026
- Press releaseBusiness Wire
Fulgent Reports First Quarter 2026 Financial Results
- Press releaseBusiness Wire
Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting
- Press releaseBusiness Wire
Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026
- Press releaseGlobe Newswire
FULGENT INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, Inc. on Behalf of Fulgent Stockholders and Encourages Investors to Contact the Firm
- Press releaseBusiness Wire
FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc.
- Press releaseGlobe Newswire
FLGT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Fulgent Genetics Inc.
- Press releaseGlobe Newswire
FLGT SHAREHOLDER ALERT: Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
- Press releaseBusiness Wire
FULGENT GENETICS INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
- Press releaseBusiness Wire
Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx
- Press releaseGlobe Newswire
Fulgent Genetics, Inc. Investigated by the Portnoy Law Firm
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
- Press releaseGlobe Newswire
Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
- NewsAvi Kapoor
Nasdaq Down Over 1%; Dell Shares Jump After Q4 Results
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- NewsAvi Kapoor
Dow Dips Over 600 Points; US Producer Prices Increase In January
- Press releaseBusiness Wire
Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results
- News
Earnings Preview: Fulgent Genetics
- Press releaseBusiness Wire
Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026
- Press releaseBusiness Wire
Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx
- Press releaseBusiness Wire
Fulgent to Participate in Upcoming Conferences
- Press releaseBusiness Wire
Fulgent Reports Third Quarter 2025 Financial Results
- Press releaseBusiness Wire
Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference
- Press releaseBusiness Wire
Fulgent to Announce Third Quarter 2025 Financial Results on Friday, November 7, 2025
- Press releaseBusiness Wire
Fulgent Reports Second Quarter 2025 Financial Results
- Press releaseBusiness Wire
Fulgent Genetics Receives EU CE Mark for FulgentExome & FulgentPLM
- Press releaseBusiness Wire
Fulgent Reports First Quarter 2025 Financial Results
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.